The research team want to investigate whether digital support, an app under preventive hormonal breast cancer treatment can lead to less late side effects, better quality of life and increased adherence to treatment.

开始日期2021-10-25

申办/合作机构

Region Stockholm

[+5]

EUCTR2013-005573-51-SE / Not yet recruiting临床4期

A 12-week, multicenter, cross-over, placebo-controlled, double-blind study to determine the impact of QVA149 (indacaterol/glycopyrronium) 85/43 µg on nocturnal oxygen levels in Chronic Obstructive Pulmonary Disease (COPD). - DuoSleep

开始日期2014-07-31

申办/合作机构

Novartis Sverige AB

EUCTR2004-005045-35-SE / Not yet recruitingN/A

A multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug naïve patients with type 2 diabetes

开始日期2005-02-17

申办/合作机构

Novartis Sverige AB

100 项与 Novartis Sverige AB 相关的临床结果

登录后查看更多信息

0 项与 Novartis Sverige AB 相关的专利（医药）

登录后查看更多信息

项与 Novartis Sverige AB 相关的文献（医药）

2024-05-11·European Journal of Preventive Cardiology

Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research

Review

作者: Neely, R Dermot G ; Kamstrup, Pia R ; Costa-Scharplatz, Madlaina ; Nissen, Steven ; Nordestgaard, Børge G ; Haghikia, Arash ; Abbas, Cheryl ; Landmesser, Ulf

AbstractLipoprotein(a) (Lp(a)) is a genetically determined causal risk factor for cardiovascular disease including coronary heart disease, peripheral arterial disease, ischaemic stroke, and calcific aortic valve stenosis. Clinical trials of specific and potent Lp(a)-lowering drugs are currently underway. However, in clinical practice, widespread assessment of Lp(a) is still lacking despite several guideline recommendations to measure Lp(a) at least once in a lifetime in all adults to identify those at high or very high risk due to elevated levels. The present review provides an overview of key findings from observational and genetic Lp(a) studies, highlights the main challenges in observational Lp(a) studies, and proposes a minimum set of requirements to enhance the quality and harmonize the collection of Lp(a)-related data. Adherence to the recommendations set forth in the present manuscript is intended to enhance the quality of future observational Lp(a) studies, to better define thresholds for increased risk, and to better inform clinical trial design. The recommendations can also potentially assist in the interpretation and generalization of clinical trial findings, to improve care of patients with elevated Lp(a) and optimize treatment and prevention of cardiovascular disease.

2023-10-03·Acta Oncologica

Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort study

Article

作者: Starklint, Jørn ; Svingel, Lise Skovgaard ; Borg Clausen, Mette ; Christensen, Sarah Friis ; Paulsson, Björn ; Bak, Marie ; Severinsen, Marianne Tang ; Hagemann Hilsøe, Morten ; Stenling, Anna ; Frederiksen, Henrik ; Mikkelsen, Ellen Margrethe ; Kjærsgaard, Anders ; Stentoft, Jesper ; Christiansen, Christian Fynbo ; Andersen, Christen Lykkegaard ; Hasselbalch, Hans Carl

BACKGROUNDPatients with myeloproliferative neoplasms (MPNs) suffer from substantial symptoms and risk of debilitating complications, yet observational data on their labor market affiliation are scarce.MATERIAL AND METHODSWe conducted a descriptive cohort study using data from Danish nationwide registries, including patients diagnosed with MPN in 2010-2016. Each patient was matched with up to ten comparators without MPN on age, sex, level of education, and region of residence. We assessed pre- and post-diagnosis labor market affiliation, defined as working, unemployed, or receiving sickness benefit, disability pension, retirement pension, or other health-related benefits. Labor market affiliation was assessed weekly from two years pre-diagnosis until death, emigration, or 31 December 2018. For patients and comparators, we reported percentage point (pp) changes in labor market affiliation cross-sectionally from week -104 pre-diagnosis to week 104 post-diagnosis.RESULTSThe study included 3,342 patients with MPN and 32,737 comparators. From two years pre-diagnosis until two years post-diagnosis, a larger reduction in the proportion working was observed among patients than comparators (essential thrombocythemia: 10.2 [95% CI: 6.3-14.1] vs. 6.8 [95% CI: 5.5-8.0] pp; polycythemia vera: 9.6 [95% CI: 5.9-13.2] vs. 7.4 [95% CI: 6.2-8.7] pp; myelofibrosis: 8.1 [95% CI: 3.0-13.2] vs. 5.8 [95% CI: 4.2-7.5] pp; and unclassifiable MPN: 8.0 [95% CI: 3.0-13.0] vs. 7.4 [95% CI: 5.7-9.1] pp). Correspondingly, an increase in the proportion of patients receiving sickness benefits including other health-related benefits was evident around the time of diagnosis.CONCLUSIONOverall, we found that Danish patients with essential thrombocythemia, polycythemia vera, myelofibrosis, and unclassifiable MPN had slightly impaired labor market affiliation compared with a population of the same age and sex. From two years pre-diagnosis to two years post-diagnosis, we observed a larger reduction in the proportion of patients with MPN working and a greater proportion receiving sickness benefits compared with matched individuals.

2023-09-01·Journal of Cancer Research and Clinical Oncology

Characterization of clinicopathological features, treatment practices, and outcomes among Finnish advanced breast cancer patients in real-life clinical practice

Article

作者: Carlqvist, Peter ; Vertuani, Simona ; Holm, Barbro ; Ellonen, Antti ; Saarinen, Silva ; Utriainen, Meri ; Heinolainen, Krista ; Karlsson, Antti ; Mandelin, Jami

AbstractPurposeIn recent years, several new targeted therapies have emerged for advanced breast cancer (aBC). However, real-life data specific to aBC and different breast cancer subtypes are scarce. This retrospective cohort study was designed to describe the distribution of aBC subtypes, incidence, treatment patterns, survival, and PIK3CA hotspot mutation frequency.MethodsThe study included all patients in the Hospital District of Southwest Finland diagnosed with aBC between 2004 and 2013 and with a sample available in Auria Biobank. In addition to registry-based data collection, 161 HR+/HER2− aBCs were screened for PIK3CA mutations.ResultsAltogether, 54.7% of the 444 patients included in the study had luminal B subtype. The smallest representations were in HR−/HER2+ (4.5%) and triple-negative (5.6%) subgroups. The percentage of aBC among all diagnosed breast cancers increased until 2010, after which it remained stable. The triple-negative cancers were associated with shorter median overall survival (5.5 months) compared to other subgroups (16.5–24.6 months). Most (84%) triple-negative cancers also metastasized during the first two years, whereas this was more evenly distributed over time in other subgroups. Of the HR+/HER2− tumors, 32.3% harbored a PIK3CA hotspot mutation. These patients, however, did not have inferior survival compared to patients with PIK3CA wild-type cancers.ConclusionThis study described real-world aBC subgroups and indicated that the clinical outcomes of subgroups vary. Although PIK3CA hotspot mutations did not lead to inferior survival, they are relevant as possible treatment targets. Overall, these data could be utilized to further evaluate the subgroup-specific medical needs in breast cancer.

100 项与 Novartis Sverige AB 相关的药物交易

登录后查看更多信息

100 项与 Novartis Sverige AB 相关的转化医学

登录后查看更多信息